PubMed Health⌕ Search

Biomedical subjects

B Furman

Publications and source records attributed to B Furman.

12 recordsLinked to original sources
PubMed1988

Return of the question "why": advantages of exploring pre-existing explanations.

We suggest that there are many advantages in thoroughly exploring the causal explanations given by clients or members of their social network to account for their problems. Specific interviewing techniques are presented to uncover clients' causal explanations or their impressions about the causal explanations of others. Various advantages of exploring these explanations are discussed. They include improved cooperation, development of "systemic empathy," detachment from the explanations of other professionals, recognition and avoidance of coalitions, loosening of firmly held explanations, dilution of noxious explanations, generation of new and positive explanations toward solutions, and taking a bird's-eye view or meta position about such explanations. We conclude that acceptance and appreciation of the human tendency to believe in causal explanations is a fruitful way to enhance interaction between clinicians and clients.

Communication↗
PubMed1985

Chylomicrons from patients with type V hyperlipoproteinemia inhibit platelet function.

Platelet aggregation and [14C]serotonin release induced by collagen and also by ADP and thrombin were significantly decreased in patients with primary Type V hyperlipoproteinemia. Platelets derived from these patients lost their hyporesponsiveness to thrombin and ADP (but not to collagen) after washings and isolation from their plasma environment. On incubation of platelets derived from normolipidemic controls with plasma derived from patients, platelet aggregation and [14C]serotonin release were lowered by 20% and 30%, respectively. On incubation of these platelets with 100 mg/dl of chylomicron triglyceride, a 40% reduction in both platelet aggregation and [14C]serotonin release was observed. The inhibition of platelet activity was positively correlated with chylomicron concentration up to a concentration of 225 mg/dl by chylomicron triglyceride. In 2 patients, bezafibrate administration (600 mg/day) resulted in marked reduction of plasma triglyceride concentration and a parallel improvement in platelet function. The platelet hyporesponsiveness in patients with Type V hyperlipoproteinemia appears to be a consequence of platelet-chylomicron interaction. This depressed platelet function may be responsible for the absence of overt atherosclerosis noted in these patients.

Adenosine Diphosphate↗